Immunotherapy
Finding ways to stimulate the body's immune system to help attack cancer cells is a growing area of research at The Institute of Cancer Research.
Clinical trials led by the ICR and our hospital partner The Royal Marsden have shown that the immunotherapy drug pembrolizumab can help extend the lives of some patients with advanced head and neck cancer, and prostate cancer.
The use of 'oncolytic' viruses, which can kill cancer cells both directly and by directing the immune system against them, is also an exciting area of research being explored by ICR researchers.
This page highlights recent news stories, blog posts and videos that concern immunotherapy research at the ICR.
Related pages
Latest ICR News
Remembering former ICR Chief Executive Professor Peter Garland
The ICR reflects on the legacy of Professor Peter Garland CBE, who served as Chief Executive from 1989 to 1999 and died on 5 March.
.png?sfvrsn=38d02ad6_1 "PW head and shoulders in garden_expand.jpg (1)")
The ICR’s Professor Paul Workman elected Fellow of the American Association of Cancer Research Academy
The Institute of Cancer Research, London, is delighted to announce that Professor Paul Workman has been elected as a Fellow of The American Association for Cancer Research (AACR) Academy.